Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers

Completed · Phase 1

Conditions studied: Healthy

In brief

This study is designed to assess the effects of two doses of FTY720 on lung (pulmonary) and cardiac (heart) functions in healthy volunteers.

Key facts

Study ID: NCT00416845
Run by: Novartis
People needed: 39
Starts: 2006-10-01
Last updated by the study team: 2010-06-04

Who can join

Age: 19 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Healthy, non-smoking,(ie. 6 months w/o the use of nicotine or nicotine containing products), male or female subjects.
Female subjects must be either surgically sterilized (including bilateral tubal ligation) at least 6 months or post-menopausal. Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion and menopause will be confirmed by a plasma FSH level of >40 IU/L.
Male subjects agree to refrain from sperm donation from check-in until 30 days beyond the conclusion of all study events.
Male subjects must agree to the use of condoms with spermicide with sexual intercourse from 14 days prior to check-in until 30 days beyond the last dose of study drug.
Resting heart rate ≥ 50 beats per minute (bpm)

You may not qualify if…

History or presence of any clinically significant events, which in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results.
Subjects with systolic blood pressure < 90 mmHg or diastolic blood pressure < 50 mmHg
Male subjects with a QTcB > 450 msec
Female subjects with a QTcB > 470 msec
Subjects with pulmonary symptoms, history of exercise-induced asthma, asthma or chronic obstructive pulmonary disease (COPD)
Use of any prescription drug within 1 month of starting the study
Positive urine screen for alcohol or drugs at screening, unless the test is shown to be falsely positive on confirmation testing.
Hemoglobin < 12g/dL
Donation of blood or significant blood loss within 56 days prior to check in.
Donation of plasma within 7 days prior check in.
Participation in an investigational study within 30 days prior to check in.
Positive screening test for HIV or Hepatitis B or C.
A past history of cigarette smoking of > 10 pack-years or use of nicotine or nicotine-containing products 6 months prior to dosing.
Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

Novartis Investigative Site — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.